4.5 Article

A cross-reactive pH-dependent EGFR antibody with improved tumor selectivity and penetration obtained by structure-guided engineering

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Biotechnology & Applied Microbiology

A highly stable human single-domain antibody-drug conjugate exhibits superior penetration and treatment of solid tumors

Yanling Wu et al.

Summary: This study reports the identification of a fully human single-domain antibody (UdAb), n501, which shows high stability and strong tumor penetration. The findings suggest that UdAb-based antibody-drug conjugates have the potential to be effective antitumor therapeutics for solid tumors.

MOLECULAR THERAPY (2022)

Article Biochemistry & Molecular Biology

Antibody mutations favoring pH-dependent binding in solid tumor microenvironments: Insights from large-scale structure-based calculations

Wanlei Wei et al.

Summary: Antibody-based therapeutics for tumor treatment have seen rapid growth, but safety remains a concern. Incorporating histidyl pH-switches in antibodies under acidic conditions allows for selective targeting of tumors and improved safety. Computational analysis suggests that specific residue mutations and complementarity-determining region positions could enhance pH-dependent binding.

PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS (2022)

Article Medicine, Research & Experimental

Antibodies to watch in 2021

Helene Kaplon et al.

Summary: The year 2020 saw significant developments in the field of antibody therapeutics, particularly in response to the COVID-19 pandemic. Several antibody products were granted emergency use authorization, and new antibody treatments received first approvals in the US or EU.
Article Oncology

Antibody Co-Administration Can Improve Systemic and Local Distribution of Antibody-Drug Conjugates to Increase In Vivo Efficacy

Jose F. Ponte et al.

Summary: A study found that co-administration of unconjugated antibody can improve the efficacy of ADC, especially in low expression models. By reducing target-antigen-mediated clearance in normal tissue, the co-administered antibody can increase the systemic exposure of ADC, improve tumor tissue penetration, and enhance ADC efficacy.

MOLECULAR CANCER THERAPEUTICS (2021)

Article Oncology

Predicting Therapeutic Antibody Delivery into Human Head and Neck Cancers

Guolan Lu et al.

CLINICAL CANCER RESEARCH (2020)

Review Oncology

Nimotuzumab for Patients With Inoperable Cancer of the Head and Neck

Tania Crombet Ramos et al.

FRONTIERS IN ONCOLOGY (2020)

Article Biotechnology & Applied Microbiology

Engineering a HER2-specific antibody-drug conjugate to increase lysosomal delivery and therapeutic efficacy

Jeffrey C. Kang et al.

NATURE BIOTECHNOLOGY (2019)

Article Multidisciplinary Sciences

VISTA is an acidic pH-selective ligand for PSGL-1

Robert J. Johnston et al.

NATURE (2019)

Article Oncology

Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate

Andrew C. Phillips et al.

MOLECULAR CANCER THERAPEUTICS (2018)

Article Biochemistry & Molecular Biology

EGFR Ligands Differentially Stabilize Receptor Dimers to Specify Signaling Kinetics

Daniel M. Freed et al.

Review Oncology

Tumour acidosis: from the passenger to the driver's seat

Cyril Corbet et al.

NATURE REVIEWS CANCER (2017)

Article Medicine, Research & Experimental

ABodyBuilder: Automated antibody structure prediction with data-driven accuracy estimation

Jinwoo Leem et al.

Article Oncology

ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope

Andrew C. Phillips et al.

MOLECULAR CANCER THERAPEUTICS (2016)

Article Oncology

Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody

Edward B. Reilly et al.

MOLECULAR CANCER THERAPEUTICS (2015)

Review Pharmacology & Pharmacy

The ErbB/HER family of protein-tyrosine kinases and cancer

Robert Roskoski

PHARMACOLOGICAL RESEARCH (2014)

Article Biotechnology & Applied Microbiology

Cetuximab-mediated Tumor Regression Depends on Innate and Adaptive Immune Responses

Xuanming Yang et al.

MOLECULAR THERAPY (2013)

Article Biochemistry & Molecular Biology

Increasing Serum Half-life and Extending Cholesterol Lowering in Vivo by Engineering Antibody with pH-sensitive Binding to PCSK9

Javier Chaparro-Riggers et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2012)

Review Oncology

Antibody therapy of cancer

Andrew M. Scott et al.

NATURE REVIEWS CANCER (2012)

Article Biotechnology & Applied Microbiology

Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization

Tomoyuki Igawa et al.

NATURE BIOTECHNOLOGY (2010)

Review Biotechnology & Applied Microbiology

The safety and side effects of monoclonal antibodies

Trevor T. Hansel et al.

NATURE REVIEWS DRUG DISCOVERY (2010)

Article Multidisciplinary Sciences

Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling

Jamie B. Spangler et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)

Article Multidisciplinary Sciences

Antibodies specifically targeting a locally misfolded region of tumor associated EGFR

Thomas P. J. Garrett et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)

Review Multidisciplinary Sciences

Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation

Matthew G. Vander Heiden et al.

SCIENCE (2009)

Review Oncology

Novel anticancer targets: revisiting ERBB2 and discovering ERBB3

Jose Baselga et al.

NATURE REVIEWS CANCER (2009)

Review Pharmacology & Pharmacy

Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance

Greg M. Thurber et al.

ADVANCED DRUG DELIVERY REVIEWS (2008)

Review Oncology

The biological properties of cetuximab

Bruno Vincenzi et al.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2008)

Review Cell Biology

EGFR family: Structure physiology signalling and therapeutic targets

Antony W. Burgess

GROWTH FACTORS (2008)

Article Oncology

Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids

Margaret E. Ackerman et al.

MOLECULAR CANCER THERAPEUTICS (2008)

Article Medicine, General & Internal

Cetuximab for the treatment of colorectal cancer

Derek J. Jonker et al.

NEW ENGLAND JOURNAL OF MEDICINE (2007)

Review Immunology

Humanized mice in translational biomedical research

Leonard D. Shultz et al.

NATURE REVIEWS IMMUNOLOGY (2007)

Article Medicine, General & Internal

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

D Cunningham et al.

NEW ENGLAND JOURNAL OF MEDICINE (2004)

Review Oncology

Why do cancers have high aerobic glycolysis?

RA Gatenby et al.

NATURE REVIEWS CANCER (2004)

Review Oncology

EGF receptor ligands

RC Harris et al.

EXPERIMENTAL CELL RESEARCH (2003)

Article Multidisciplinary Sciences

A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor

AA Jungbluth et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)

Article Biotechnology & Applied Microbiology

Rational cytokine design for increased lifetime and enhanced potency using pH-activated histidine switching

CA Sarkar et al.

NATURE BIOTECHNOLOGY (2002)

Review Biochemistry & Molecular Biology

The ErbB signaling network: receptor heterodimerization in development and cancer

MA Olayioye et al.

EMBO JOURNAL (2000)